In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell
therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in …

The application of chimeric antigen receptor (CAR) T-cell therapy as a tumor immunotherapy
has received great interest in recent years. This therapeutic approach has been used to treat …

Gastrointestinal cancers (GICs) and neuroendocrine tumors (NETs) are often refractory to
therapy after metastasis. Adoptive cell therapy using chimeric antigen receptor (CAR) T …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

T-cell exhaustion is a phenomenon that represents the dysfunctional state of T cells in
chronic infections and cancer and is closely associated with poor prognosis in many …

The third leading cause of cancer-related deaths in the United States is pancreatic cancer,
more than 95% of which is pancreatic ductal adenocarcinoma (PDA). The incidence rate of …

Simple Summary The primary issue of adoptive cell therapy is the poor in vivo persistence.
In this context, it is necessary to clarify the fundamental mechanisms of T cell dysfunction …

Most studies on genetic engineering technologies for cancer immunotherapy based on
allogeneic donors have focused on adaptive immunity. However, the main limitation of such …

Over the past few decades, advances in immunological knowledge have led to the
identification of novel immune checkpoints, reinvigorating cancer immunotherapy …

Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate
tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents …